Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.

Maria Luisa AznarTheodore K MarrasAhmed Said ElshalMahtab MehrabiSarah K Brode

Published in: BMC pharmacology & toxicology (2019)

Patients with NTM PD treated with low-dose intravenous amikacin frequently developed ototoxicity, which was associated with female sex, and total dose of amikacin per bodyweight. Physicians should carefully consider dose, treatment duration, and long term prognosis in balancing risks and benefits of intravenous amikacin in NTM PD.

Keyphrases

low dose
high dose
primary care
randomized controlled trial
systematic review
pulmonary hypertension
risk assessment